Aim Immunotech Inc (AIM) |
|
2.09 -0.17 (-7.52%)
|
03-05 07:27 |
|
Open: |
2.23 |
Pre. Close: |
2.26 |
|
High:
|
2.2501 |
Low:
|
2 |
|
Volume:
|
2,305,613 |
Market Cap:
|
85M |
|
|
|
|
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. The company is headquartered in Ocala, Florida and currently employs 31 full-time employees. The firm is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The firm's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The firm's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.252 - 2.271 |
2.271 - 2.283 |
|
Low:
|
1.965 - 1.984 |
1.984 - 1.996 |
|
Close:
|
2.065 - 2.095 |
2.095 - 2.114 |
|
Technical analysis |
as of: 2021-03-04 5:04:22 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 3.07 One year: 3.57 |
| Support: |
Support1: 1.94 Support2: 1.61 |
| Resistance: |
Resistance1: 2.63 Resistance2: 3.06 |
| Pivot: |
2.44 |
| Moving Average: |
MA(5): 2.26 MA(20): 2.49 
MA(100): 2.10 MA(250): 2.33 |
| MACD: |
MACD(12,26): Signal(9): 0.06 |
| Stochastic oscillator: |
%K(14,3): 17.66 %D(3): 21.46 |
| RSI: |
RSI(14): 40.27 |
| 52-week: |
High: 7.11 Low: 1.60 Change(%): -0.5 |
| Average Vol(K): |
3-Month: 391062 10-Days: 207618 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.AIM has closed above bottom band by 6.5%. Bollinger Bands are 63.7% wider than normal. The large width of the bands suggest high volatility as compared to AIM's normal range. The bands have been in this wide range for 19 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 04 Mar 2021
AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th - Yahoo Finance
Wed, 24 Feb 2021
AIM ImmunoTech Inc (AIM) Stock Has Fallen -5.20% This Week: Buy, Hold, or Sell? - InvestorsObserver
Wed, 24 Feb 2021
AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer - Yahoo Finance
Tue, 16 Feb 2021
AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy - Yahoo Finance
Wed, 10 Feb 2021
AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands - Yahoo Finance
Wed, 10 Feb 2021
Is AIM ImmunoTech Inc (AIM) The Right Choice in Biotechnology? - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
40 |
| Shares Float (M) |
39 |
|
% Held by Insiders
|
2.00 |
|
% Held by Institutions
|
2.10 |
|
Shares Short (K)
|
1,920 |
|
Shares Short P. Month (K)
|
2,690 |
Stock Financials |
|
EPS
|
-5.873 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
2.140 |
|
Profit Margin
|
|
|
Operating Margin
|
-6562.25 |
|
Return on Assets (ttm)
|
-25.1 |
|
Return on Equity (ttm)
|
-42.2 |
|
Qtrly Rev. Growth
|
37.9 |
|
Gross Profit (p.s.)
|
-0.019 |
|
Sales Per Share
|
0.005 |
|
EBITDA (p.s.)
|
-0.304 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-9 |
|
Levered Free Cash Flow (M)
|
-7 |
Stock Valuations |
|
PE Ratio
|
-0.36 |
|
PEG Ratio
|
|
|
Price to Book value
|
0.98 |
|
Price to Sales
|
423.22 |
|
Price to Cash Flow
|
-8.86 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
